The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Antitumor effects of bisphosphonates
Open accessAbstract
BACKGROUND: Bisphosphonates are widely used to treat skeletal complications of malignancy. These drugs accumulate in bone where they inhibit osteoclastic bone resorption and reduce the local release of factors that stimulate tumor growth. The mechanism of action of bisphosphonates is dependent on chemical structure: Nonnitrogen-containing compounds (e.g., etidronate, clodronate) are metabolized into cytotoxic analogues of ATP, whereas the more potent nitrogen-containing compounds (N-BPs; e.g., pamidronate, ibandronate, zoledronic acid) inhibit protein prenylation, thus affecting cell function and survival. Because protein prenylation is required by all cells, not just osteoclasts, the possibility arises that N-BPs could also affect the viability of tumor cells. METHODS: Several groups have investigated the in vitro effects of bisphosphonates, either alone or in combination with other antineoplastic agents, on the viability and metastatic properties of many tumor cell types. Similarly, the effect of bisphosphonate treatment on osteolysis and tumor burden has been studied in a variety of animal tumor models. RESULTS: In vitro, submicromolar concentrations of N-BPs inhibited tumor cell adhesion and reduced invasion through extracellular matrix. At higher concentrations, antiproliferative and proapoptotic effects have been reported. In animal models of bone metastases, bisphosphonate treatment markedly reduced osteolytic lesions. There is also evidence of a reduction in tumor burden in bone and occasionally in other organs. Survival may be prolonged, but bisphosphonates do not appear to inhibit the growth of primary soft tissue tumors or orthotopic xenografts. CONCLUSIONS: The cell culture data clearly demonstrated that N-BPs exert antitumor properties and interact synergistically with other antineoplastic agents. As bisphosphonates accumulate in bone, they can also exert cytostatic effects on tumor cells in bone metastases, either directly or indirectly via osteoclast inhibition and alterations in the bone microenvironment. Further in vivo research is now required to optimize the dosing regimen of N-BPs to exploit fully their antitumor potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035295 · Cited by 854
Self-citationGuise, T. A., Yin, J. J., Taylor, S. D., Kumagai, Y., Dallas, M., Boyce, B. F., Yoneda, T., & Mundy, G. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118947 · Cited by 851
Kunzmann, V., Bauer, E., Feurle, J., Tony, F. W., & Wilhelm, M. (2000) · Blood · doi:10.1182/blood.v96.2.384 · Cited by 669
Boissier, S., Ferreras, M., Peyruchaud, O., Magnetto, S., Ebetino, F. H., Colombel, M. C., Delmas, P. D., Delaissé, J., & Clézardin, P. (2000) · PubMed · Cited by 573
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
Bisphosphonates induce apoptosis in human breast cancer cell lines
Senaratne, S. G., Pirianov, G., Mansi, J. L., Arnett, T. R., & Langrish, V (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1131 · Cited by 428
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki, A., Boyce, B. F., Story, B. M., Wright, K. R., Chapman, M., Boyce, R. W., Mundy, G. R., & Yoneda, T. (1995) · PubMed · Cited by 417
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., & Martin, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116422 · Cited by 412
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity
Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G. G., & Croucher, P. I. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2713086.x · Cited by 398
The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals
Jung, A., Bisaz, S., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547227 · Cited by 381
Bisphosphonate treatment inhibits the growth of prostate cancer cells.
Lee, M. V., Fong, E. D. M., Singer, F. R., & Guenette, R. S. (2001) · PubMed · Cited by 364
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body, J. J., Bartl, R., Burckhardt, P., Delmas, P. D., Diel, I. J., Fleisch, H., Kanis, J. A., Kyle, R. A., Mundy, G. R., Paterson, A. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3890 · Cited by 359
The acute-phase response after bisphosphonate administration
Adami, S., Bhalla, A. K., Dorizzi, R., Montesanti, F., Rosini, S., Salvagno, G., & Lo Cascio, V. (1987) · Calcified Tissue International · doi:10.1007/bf02556671 · Cited by 357
Jagdev, S. P., Coleman, R. E., Shipman, C. M., Rostami-H, A., & Croucher, P. I. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1727 · Cited by 346
Boissier, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F. H., Delmas, P. D., & Clézardin, P. (1997) · PubMed · Cited by 343
Structure-activity relationships of various bisphosphonates
Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983) · Calcified Tissue International · doi:10.1007/bf02405012 · Cited by 306
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118841 · Cited by 305
Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
Bisphosphonates Induce Breast Cancer Cell Death In Vitro
Fromigue, O., Lagneaux, L., & Body, J.-J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.11.2211 · Cited by 276
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
Aparicio, A., Gardner, A., Tu, Y., Savage, A., Berenson, J., & Lichtenstein, A. (1998) · Leukemia · doi:10.1038/sj.leu.2400892 · Cited by 259
Yoneda, T., Sasaki, A., Dunstan, C., Williams, P. J., Bauss, F., De Clerck, Y. A., & Mundy, G. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119435 · Cited by 247
Hiraga, T., Williams, P. J., Mundy, G. R., & Yoneda, T. (2001) · PubMed · Cited by 241
Bisphosphonates: Preclinical Aspects and Use in Osteoporosis
Fleisch, H. A. (1997) · Annals of Medicine · doi:10.3109/07853899708998743 · Cited by 220
Shipman, C. M., Croucher, P. I., Russell, R. G. G., Helfrich, M. H., & Rogers, M. J. (1998) · PubMed · Cited by 216
Pennanen, N., Lapinjoki, S., Urtti, A., & Mönkkönen, J. (1995) · Pharmaceutical Research · doi:10.1023/a:1016281608773 · Cited by 211
Thiébaud, D., Sauty, A., Burckhardt, P., Leuenberger, P., Sitzler, L., Green, J. R., Kandra, A., Zieschang, J., & Palacios, P. I. D. (1997) · Calcified Tissue International · doi:10.1007/s002239900353 · Cited by 206
Self-citationMMP Inhibition and Downregulation by Bisphosphonates
TERONEN, O., HEIKKILÄ, P., KONTTINEN, Y. T., LAITINEN, M., SALO, T., HANEMAAIJER, R., TERONEN, A., MAISI, P., & SORSA, T. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07702.x · Cited by 200
Derenne, S., Amiot, M., Barillé, S., Collette, M., Robillard, N., Berthaud, P., Harousseau, J.-L., & Bataille, R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.12.2048 · Cited by 195
Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation
GROTZ, W., NAGEL, C., POESCHEL, D., CYBULLA, M., PETERSEN, K.-G., UHL, M., STREY, C., KIRSTE, G. D., OLSCHEWSKI, M., REICHELT, A., et al. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271530 · Cited by 190
Vγ2Vδ2 T-cell receptor–mediated recognition of aminobisphosphonates
Das, H., Wang, L., Kamath, A., & Bukowski, J. F. (2001) · Blood · doi:10.1182/blood.v98.5.1616 · Cited by 178
Peyruchaud, O., Winding, B., Pécheur, I., Serre, C.-M., Delmas, P., & Clézardin, P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.11.2027 · Cited by 173
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen, S. S., Väänänen, H. K., Härkönen, P. L., & Lakkakorpi, P. T. (2002) · PubMed · Cited by 162
Dallas, S. L., Garrett, I. R., Oyajobi, B. O., Dallas, M. R., Boyce, B. F., Bauss, F., Radl, J., & Mundy, G. R. (1999) · Blood · doi:10.1182/blood.v93.5.1697 · Cited by 137
Tassone, P., Forciniti, S., Galea, E., Morrone, G., Turco, M. C., Martinelli, V., Tagliaferri, P., & Venuta, S. (2000) · Leukemia · doi:10.1038/sj.leu.2401770 · Cited by 136
Gordon, C. M., Grace, E., Emans, S. J., Goodman, E., CRAWFORD, M. H., & LeBoff, M. S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.136 · Cited by 123
Bisphosphonates inhibit IL-6 production by human osteoblast-like cells
Giuliani, N. (1998) · Scandinavian Journal of Rheumatology · doi:10.1080/030097498441155 · Cited by 121
Inhibition of antigen-presenting cell function by alendronate in vitro
Sansoni, P., Passeri, G., Fagnoni, F. F., Mohagheghpour, N., Snelli, G., Brianti, V., & Engleman, E. G. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101115 · Cited by 105
Alendronate Reduces Adhesion of Human Osteoclast-like Cells to Bone and Bone Protein-Coated Surfaces
Colucci, S. C., Minielli, V., Zambonin, G., Cirulli, N., Mori, G., Serra, M., Patella, V., Zallone, A. Z., & Grano, M. (1998) · Calcified Tissue International · doi:10.1007/s002239900519 · Cited by 93
Magnetto, S., Boissier, S., Delmas, P. D., & Clézardin, P. (1999) · International Journal of Cancer · Cited by 89
Bellahcène, A., & CASTRONOVO, V. (1997) · PubMed · Cited by 85
Goltzman, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13073 · Cited by 80
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma
Radl, J., Croese, J. W., ZURCHER, C., van den Enden-Vieveen, M. H. M., Brondijk, R. J., Kazil, M., Haaijman, J. J., Reitsma, P. H., & Bijvoet, O. L. M. (1985) · Cancer · Cited by 79
Hall, D. G., & Stoica, G. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090211 · Cited by 74
Inhibition by diphosphonates of bone resorption induced by the walker tumor of the rat
Jung, A., Bornand, J., Mermillod, B., Edouard, C. M., & Meunier, P. J. (1985) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/0278-2391(85)90276-9 · Cited by 72
Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.
Stearns, M. E., & Wang, M. (1996) · PubMed · Cited by 70
Inhibition of Matrix Metalloproteinase-1 by Dichloromethylene Bisphosphonate (Clodronate)
Teronen, O. P., Konttinen, Y. T., Lindqvist, C., Salo, T. A., Ingman, T., Lauhio, A., Ding, Y., Santavirta, S. S., Valleala, H., & Sorsa, T. A. (1997) · Calcified Tissue International · doi:10.1007/s002239900295 · Cited by 68
A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells
Takahashi, R., Shimazaki, C., Inaba, T., Okano, A., Hatsuse, M., Okamoto, A., Hirai, H., Ashihara, E., & Nakagawa, M. (2001) · Leukemia Research · doi:10.1016/s0145-2126(00)00087-4 · Cited by 61
Kostenuik, P. J., Orr, F. W., Suyama, K. L., & Singh, G. (1993) · PubMed · Cited by 58
Krempien, B., Wingen, F.-J., Eichmann, T., Müller, M., & Schmähl, D. (2009) · Oncology · doi:10.1159/000226528 · Cited by 58
Pollard, M., & Luckert, P. H. (1985) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/75.5.949 · Cited by 55
Pecherstorfer, M., Jilch, R., Sauty, A., et al. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.147 · Cited by 49
Stearns, M. E., & Wang, M. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006524610591 · Cited by 43
Cruz, J. C., Alsina, M., Craig, F. E., Yoneda, T., Anderson, J. L., Dallas, M., & Roodman, G. D. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00618-x · Cited by 37
Progression Delay of Prostate Tumor Skeletal Metastasis Effects by Bisphosphonates
Yu-Cheng, S., Geldof, A. A., Newling, D. W. W., & Rao, B. R. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)36890-8 · Cited by 33
Alendronate blocks TGF-β1 stimulated collagen 1 degradation by human prostate PC-3 ML cells
Stearns, M. E. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006513413583 · Cited by 30
Alvarez, E., Westmore, M. S., Galvin, R. J. S., Clapp, C. L., Considine, E. L., Smith, S. J., Keyes, K. A., Iversen, P. W., Delafuente, D. M., Sulaimon, S. S., et al. (2003) · PubMed · Cited by 29
Nemoto, R., Sato, S., Nishijima, Y., et al. (1990) · The Journal of Urology · doi:10.1016/s0022-5347(17)39589-7 · Cited by 26
Nemoto, R., Kanoh, S., Koiso, K., & Harada, M. (1988) · The Journal of Urology · doi:10.1016/s0022-5347(17)41848-9 · Cited by 20
Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice
Nemoto, R., Nishijima, Y., Uchida, K., & Koiso, K. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.167 · Cited by 13
Response of MBT-2 bladder carcinoma-induced osteolysis to various agents
Nemoto, R., Satou, S., Mochizuki, T., & OKABE, K. (1992) · Cancer · Cited by 7
SP220K is a novel matrix serine proteinase
Thaon, S., Auberger, P., Rossi, B., & Poustis-Delpont, C. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980717)77:2<279::aid-ijc18>3.0.co;2-6 · Cited by 3
Cited by
Targeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
Giraudo, E., Inoue, M., & Hanahan, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422087 · Cited by 700
Efficient Killing of Human Colon Cancer Stem Cells by γδ T Lymphocytes
Todaro, M., D'Asaro, M., Caccamo, N., Iovino, F., Francipane, M. G., Meraviglia, S., Orlando, V., La Mendola, C., Gulotta, G., Salerno, A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804288 · Cited by 280
Mönkkönen, H., Auriola, S., Lehenkari, P., Kellinsalmi, M., Hassinen, I. E., Vepsäläinen, J., & Mönkkönen, J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706628 · Cited by 280
Structural Basis for Bisphosphonate-mediated Inhibition of Isoprenoid Biosynthesis
Hosfield, D. J., Zhang, Y., Dougan, D. R., Broun, A., Tari, L. W., Swanson, R. V., & Finn, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300511200 · Cited by 272
Metadata
- Authors
- Green, J. R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-01-23
- Volume
- 97
- Issue
- S3
- Pages
- 840-847
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2038995854
- Cited by
- 311
- References
- 64
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.